Jules Ewing

[Jules Ewing @julesewing05]

@RAH00084 At first I thought Elon had commented on your post 😅 but I do certainly concur 😁👊

[Jules Ewing @julesewing05]

#AVCT

[Avacta @avacta]

CEO Christina Coughlin and CFO Brian Hahn will be at @Jefferies Healthcare Conference, Nov 16-19 in London. Curious how pre|CISION® keeps potent payloads silent in the bloodstream and active in the tumor? Book a 1:1 via the partnering system. https://t.co/PoHwBYBgkM #AVCT

[stonks @JStonker]

CC in great company this Tuesday. More or less every major pharma attending the event too.

#AVCT

[Jules Ewing @julesewing05]

#AVCT

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

#AVCT CEO is on stage with the Global Head of Oncology Search & Evaluation at Roche on a panel titled “Prioritising the Pipeline”. 👀😂

EXACTLY the sort of person responsible for assessing external technologies and licensing opportunities.

Roche/Genentech is one of the biggest and most established ADC players in #oncology. And interestingly, so is Astellas, which is also on Tuesday's panel.

As panels go, it couldn’t get much better for @avacta

All eyes on Tuesday 👀👀👀👀

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

#AVCT CEO is on stage with the Global Head of Oncology Search & Evaluation at Roche on a panel titled “Prioritising the Pipeline”. 👀😂

EXACTLY the sort of person responsible for assessing external technologies and licensing opportunities.

Roche/Genentech is one of the biggest and most established ADC players in #oncology. And interestingly, so is Astellas, which is also on Tuesday's panel.

As panels go, it couldn’t get much better for @avacta

All eyes on Tuesday 👀👀👀👀

[Jules Ewing @julesewing05]

@JohnCleese I would like to support your business but I live in the North East - could I buy a meal and you give it to someone as a treat off me. Anyone you think - or maybe have a pay it forward scheme where folk get a freebie one day and then pay it forward another day? I’d like to help

[Jules Ewing @julesewing05]

#AVCT

[Avacta @avacta]

Watch the latest episode of our R&D Spotlight series. In the second of Avacta Chief Executive Officer @coughlin582’s deep dives into the data presented at ESMO 2026, the focus is today on AVA6000. https://t.co/Epyt8ez8Mb #AVCT

[Jules Ewing @julesewing05]

#AVCT

[Avacta @avacta]

Watch episode 16 of our R&D Spotlight series, where Avacta Chief Executive Officer @coughlin582 takes a deep dive into the AVA6103 data presented at ESMO 2026. https://t.co/Sm4KYcdPzG #AVCT

[Jules Ewing @julesewing05]

#AVCT

[Richard Hughes @hughesy0707]

The clinical data reading out of AVA6000 & 6103 is a product of Chris & her team’s execution.

These findings not only strengthen our platform, they validate our strategy of retaining IP until we believe it represents maximum value for #AVCT shareholders.

A busy Q4 ahead of us.

[Jules Ewing @julesewing05]

@coughlin582 Exciting times ahead 👌🫶

[Jules Ewing @julesewing05]

#AVCT

[Christina Coughlin @coughlin582]

Hola! Greetings from Madrid 🇪🇸

Delighted to present updates in the AVA6000 program w/ efficacy in SGC. Platform data support our clinical observations with persistent FAP expression even in deep tumor response, with prolonge FAP activity and payload release. #AVCT

#LetsDoThis

[Jules Ewing @julesewing05]

#AVCT

[Avacta @avacta]

New at #ESMO26: faridoxorubicin (AVA6000) data in salivary gland cancers show a median PFS of 11.4 months, with FAPI-PET imaging showing FAP persists as tumors respond. Poster 1549P, 12:00-12:45 PM CET.
https://t.co/lhnwd6E0Ol
#preCISION #AVCT

[Sean Dent @SeanDentBsc]

11.4m PFS for SGC 💥

#AVCT knocking it out the park!

Seems the benchmark is 6m so almost double, previously benchmark was 4m though?

3 partial and 6 minor responses but these were previously reported as 4 & 8 in the June RNS so confusion there @avacta ?

[Jules Ewing @julesewing05]

#AVCT

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

Beyond the 11.4 month PFS, the #AVCT ESMO poster provides compelling validation of the preCISION *platform*.

FAPI-PET shows FAP persists despite substantial tumour shrinkage, while drug release continues through 12 treatment cycles.

The tumour shrinks ✅
The target remains ✅
The platform keeps delivering ✅

[⛏🅾️Ⓜ️💣 @tom_the_bomb__]

Beyond the 11.4 month PFS, the #AVCT ESMO poster provides compelling validation of the preCISION *platform*.

FAPI-PET shows FAP persists despite substantial tumour shrinkage, while drug release continues through 12 treatment cycles.

The tumour shrinks ✅
The target remains ✅
The platform keeps delivering ✅

[Jules Ewing @julesewing05]

#AVCT

[Myles McNulty @MylesMcNulty]

This discovery of the self-amplifying FAP recruitment by #AVCT's pre|CISION drugs is insane.

Assuming safety and tolerability do not become issues for a patient being treated with a pre|CISION drug, then that self-amplifying FAP recruitment essentially extends out (perhaps dramatically) the number of cycles the patient can endure...

...And ultimately, continuously expands the $ total addressable market for each drug and the entire platform.

A remarkable discovery and once again astounding that the UK market is just shrugging it off.

AVA6103 is utterly dominating the best that the ADC modality has to offer. There is a visible route to it becoming the best selling oncology drug of all time - that should be clear to everyone who has followed the Avacta story.

[Jules Ewing @julesewing05]

#AVCT

[Christina Coughlin @coughlin582]

We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechanistic evidence for fibroblast recruitment, rapid and deep tumor penetration and enhanced payload exposure over traditional ADC

#LetsDoThis

[Christina Coughlin @coughlin582]

We are delighted to present 2 data sets at #ESMO26 - #AVCT Trials in Progress with AVA6103 shows some critical platform data showing mechanistic evidence for fibroblast recruitment, rapid and deep tumor penetration and enhanced payload exposure over traditional ADC

#LetsDoThis

[Jules Ewing @julesewing05]

#AVCT

[Avacta @avacta]

At #ESMO26, we’re presenting the FOCUS-01 trial design and new preclinical data for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, including activity in Enhertu®-resistant tumor models.
https://t.co/89dfmPg6j7 #preCISION #NextGenLoading #AVCT

[Avacta @avacta]

At #ESMO26, we’re presenting the FOCUS-01 trial design and new preclinical data for AVA6103 (FAP-Exd), our first Next Gen pre|CISION® PDC, including activity in Enhertu®-resistant tumor models.
https://t.co/89dfmPg6j7 #preCISION #NextGenLoading #AVCT